Cargando…

Carcinogenesis and management of human papillomavirus-associated cervical cancer

Approximately 95% of cervical cancer are caused by human papillomavirus (HPV) infection. Although it is estimated that HPV-associated cervical cancer will decrease with the widespread use of HPV vaccine, it may take time for HPV-associated cervical cancer to be eliminated. For the appropriate manage...

Descripción completa

Detalles Bibliográficos
Autores principales: Kusakabe, Misako, Taguchi, Ayumi, Sone, Kenbun, Mori, Mayuyo, Osuga, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390372/
https://www.ncbi.nlm.nih.gov/pubmed/37294390
http://dx.doi.org/10.1007/s10147-023-02337-7
_version_ 1785082465386233856
author Kusakabe, Misako
Taguchi, Ayumi
Sone, Kenbun
Mori, Mayuyo
Osuga, Yutaka
author_facet Kusakabe, Misako
Taguchi, Ayumi
Sone, Kenbun
Mori, Mayuyo
Osuga, Yutaka
author_sort Kusakabe, Misako
collection PubMed
description Approximately 95% of cervical cancer are caused by human papillomavirus (HPV) infection. Although it is estimated that HPV-associated cervical cancer will decrease with the widespread use of HPV vaccine, it may take time for HPV-associated cervical cancer to be eliminated. For the appropriate management of HPV-associated cervical cancer, it is important to understand the detailed mechanisms of cervical cancer development. First, the cellular origin of most cervical cancers is thought to be cells in the squamocolumnar junction (SCJ) of the uterine cervix. Therefore, it is important to understand the characteristics of SCJ for cervical cancer screening and treatment. Second, cervical cancer is caused by high risk HPV (HR-HPV) infection, however, the manner of progression to cervical cancer differs depending on the type of HR-HPV: HPV16 is characterized by a stepwise carcinogenesis, HPV18 is difficult to detect in precancerous lesions, and HPV52, 58 tends to remain in the state of cervical intraepithelial neoplasia (CIN). Third, in addition to the type of HPV, the involvement of the human immune response is also important in the progression and regression of cervical cancer. In this review, we demonstrate the carcinogenesis mechanism of HPV-associated cervical cancer, management of CIN, and the current treatment of CIN and cervical cancer.
format Online
Article
Text
id pubmed-10390372
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-103903722023-08-02 Carcinogenesis and management of human papillomavirus-associated cervical cancer Kusakabe, Misako Taguchi, Ayumi Sone, Kenbun Mori, Mayuyo Osuga, Yutaka Int J Clin Oncol Invited Review Article Approximately 95% of cervical cancer are caused by human papillomavirus (HPV) infection. Although it is estimated that HPV-associated cervical cancer will decrease with the widespread use of HPV vaccine, it may take time for HPV-associated cervical cancer to be eliminated. For the appropriate management of HPV-associated cervical cancer, it is important to understand the detailed mechanisms of cervical cancer development. First, the cellular origin of most cervical cancers is thought to be cells in the squamocolumnar junction (SCJ) of the uterine cervix. Therefore, it is important to understand the characteristics of SCJ for cervical cancer screening and treatment. Second, cervical cancer is caused by high risk HPV (HR-HPV) infection, however, the manner of progression to cervical cancer differs depending on the type of HR-HPV: HPV16 is characterized by a stepwise carcinogenesis, HPV18 is difficult to detect in precancerous lesions, and HPV52, 58 tends to remain in the state of cervical intraepithelial neoplasia (CIN). Third, in addition to the type of HPV, the involvement of the human immune response is also important in the progression and regression of cervical cancer. In this review, we demonstrate the carcinogenesis mechanism of HPV-associated cervical cancer, management of CIN, and the current treatment of CIN and cervical cancer. Springer Nature Singapore 2023-06-09 2023 /pmc/articles/PMC10390372/ /pubmed/37294390 http://dx.doi.org/10.1007/s10147-023-02337-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Invited Review Article
Kusakabe, Misako
Taguchi, Ayumi
Sone, Kenbun
Mori, Mayuyo
Osuga, Yutaka
Carcinogenesis and management of human papillomavirus-associated cervical cancer
title Carcinogenesis and management of human papillomavirus-associated cervical cancer
title_full Carcinogenesis and management of human papillomavirus-associated cervical cancer
title_fullStr Carcinogenesis and management of human papillomavirus-associated cervical cancer
title_full_unstemmed Carcinogenesis and management of human papillomavirus-associated cervical cancer
title_short Carcinogenesis and management of human papillomavirus-associated cervical cancer
title_sort carcinogenesis and management of human papillomavirus-associated cervical cancer
topic Invited Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390372/
https://www.ncbi.nlm.nih.gov/pubmed/37294390
http://dx.doi.org/10.1007/s10147-023-02337-7
work_keys_str_mv AT kusakabemisako carcinogenesisandmanagementofhumanpapillomavirusassociatedcervicalcancer
AT taguchiayumi carcinogenesisandmanagementofhumanpapillomavirusassociatedcervicalcancer
AT sonekenbun carcinogenesisandmanagementofhumanpapillomavirusassociatedcervicalcancer
AT morimayuyo carcinogenesisandmanagementofhumanpapillomavirusassociatedcervicalcancer
AT osugayutaka carcinogenesisandmanagementofhumanpapillomavirusassociatedcervicalcancer